WebDoctor Encyclopedia

Melanoma

Conjunctival melanoma

Conjunctival melanoma is a rare cancer of the pigment cells on the surface of the eye, often growing from primary acquired melanosis. It is treated with no-touch surgery and surface treatments, and it can recur or spread to lymph nodes, so lifelong checks matter.

Medically reviewed Last reviewed October 20, 2026

What is conjunctival melanoma?

Conjunctival melanoma is a rare cancer of the conjunctiva, the thin, clear membrane that covers the white of the eye and lines the inside of the eyelids. It develops from melanocytes, the cells that make pigment. It is different from uveal melanoma, which grows inside the eye, and it behaves more like melanoma of the skin and mucous membranes.

The disease is uncommon, with roughly one new case per million people each year. Numbers appear to be rising, particularly in people over 65 (Butt et al., 2024). Most patients are fair-skinned adults in later life.

Conjunctival melanoma often appears as a brown or pinkish patch or lump on the surface of the eye. Many cases grow from a flat, freckle-like area of pigment called primary acquired melanosis (PAM). Others grow from an existing mole (naevus) or appear without any earlier lesion.

Although it starts on the surface, conjunctival melanoma can come back locally, spread to lymph nodes in front of the ear or in the neck, and less often spread to distant organs. Early diagnosis and careful surgery at a specialist eye cancer (ocular oncology) centre give the best results.

1. Key facts at a glance

Feature Details
Type of cancer Melanoma of the conjunctiva (surface lining of the eye)
How common Very rare; about 1 per million people per year
Typical age Usually over 50; most often in the 60s and 70s
Who is affected Mostly white adults; men and women in similar numbers
Main precursor Primary acquired melanosis (PAM) with atypia
Spread Local recurrence, lymph nodes near the ear and in the neck, then distant organs
Main treatment Careful surgical removal with additional treatment to the surface of the eye
Outlook Most people survive; risk depends on location, thickness and origin

2. Types of conjunctival melanoma

Doctors describe conjunctival melanoma by where it came from and where it sits.

By origin

In a large series of 382 patients, about three-quarters of melanomas arose from PAM, around 7% from a naevus, and roughly one in five de novo, meaning with no earlier lesion (Shields et al., 2011).

Origin Share of cases Notes
From PAM About 74% Most common; often a wider, flat area of pigment
From a naevus About 7% Grows from a long-standing mole
De novo About 19% Linked to a higher risk of spread and death

By location

Location Notes
Bulbar conjunctiva Covers the white of the eye; the most common and most visible site
Limbus The edge where the white meets the cornea
Fornix The deep folds where the eyelid lining meets the eye; harder to see
Palpebral (tarsal) conjunctiva Inner surface of the eyelid; harder to see
Caruncle The small pink mound in the inner corner of the eye

Melanomas in less visible places, such as the fornix, inner eyelid or caruncle, tend to be found later and carry a higher risk (Shields et al., 2011).

How it compares with other eye melanomas

Feature Conjunctival melanoma Uveal melanoma
Where it grows Surface of the eye Inside the eye
Visible in a mirror Often Rarely
Main genes BRAF, NRAS, NF1, similar to skin melanoma GNAQ, GNA11, BAP1
Spread Lymph nodes first, then distant organs Mainly to the liver, via the blood
Treatment Surgery, cryotherapy, eye drops Radiotherapy, surgery

3. Causes and risk factors

The exact cause is not fully understood. Like skin melanoma, conjunctival melanoma often carries changes in genes such as BRAF, NRAS and NF1, and the pattern suggests that ultraviolet light plays a part in some cases (Grimes et al., 2020).

Risk factor Notes
Primary acquired melanosis with atypia The main precursor; risk rises with the degree of atypia and the size of the patch
Conjunctival naevus A mole of the eye surface; only rarely becomes cancer
Fair skin Most patients are white
Older age Risk rises sharply after 65
Sunlight exposure Probably contributes, especially on exposed parts of the eye
Immune suppression May increase risk

Most freckles and moles on the eye never become melanoma, but new or changing pigment should always be checked.

4. How does it look

On the surface of the eye

Feature Description
Colour Brown, black, or sometimes pink or skin-coloured (amelanotic)
Shape A raised nodule, often with a flatter pigmented area around it
Blood vessels Large feeder vessels may run to the lump
Size From a few millimetres to more than 1 cm
Movement Usually moves slightly with the conjunctiva over the white of the eye
Bleeding Some lumps bleed easily

Compared with a harmless mole

Feature Benign naevus Melanoma
Onset Often present since childhood New in adulthood
Change Stable for years Growing, thickening or spreading
Cysts inside Common Uncommon
Location Usually on the white of the eye May be in the fornix, eyelid or cornea
Feeder vessels Uncommon Common

Under the microscope

Melanoma cells are atypical pigment cells that have grown through the surface layer of the conjunctiva into the tissue beneath. The pathologist measures the tumour thickness and looks for ulceration, which helps predict the risk of spread.

5. Symptoms

Common signs

  • A new brown or pink spot or lump on the white of the eye or inside the eyelid
  • A change in size, colour or thickness of an existing spot
  • Redness or prominent blood vessels in one area
  • A feeling that something is in the eye

Less common symptoms

Symptom What it may mean
Bleeding from the eye surface Fragile tumour vessels
Irritation or discharge Inflammation around the tumour
Lump in front of the ear or under the jaw Possible lymph node spread
Blurred vision Growth onto the cornea, which is uncommon

When to seek medical advice

See an optician or eye doctor promptly if you notice any new pigmented spot on the eye, or a change in an existing one, particularly after the age of 40. Early melanomas are often painless, so do not wait for discomfort.

6. Diagnosis

Test Purpose
Slit-lamp examination A magnified view of the eye surface
Eyelid eversion Turning the lids to check the inner surfaces and fornices
Clinical photographs Record the lesion so change can be measured
Anterior segment OCT or ultrasound Shows depth and whether the tumour invades the eye
Biopsy Ideally an excisional biopsy that removes the whole lesion
Lymph node examination and ultrasound Checks nodes near the ear and in the neck
CT, MRI or PET-CT For thicker tumours or suspected spread
Genetic testing of the tumour Looks for BRAF or other changes relevant to drug treatment

Small cuts into the tumour can spread cells, so specialists usually prefer to remove the whole lesion in one piece where possible.

Staging

Conjunctival melanoma is staged with the TNM system:

Stage component What it describes
T (tumour) Location (bulbar or non-bulbar), number of quadrants involved, and invasion of the eyelid, eye or orbit
N (nodes) Whether regional lymph nodes contain melanoma
M (metastasis) Whether it has spread to distant organs

Sentinel lymph node biopsy

For thicker or higher-risk tumours, some centres offer a sentinel lymph node biopsy, which samples the first node that drains the area. In one Slovenian series, about one in seven of these biopsies found melanoma in the node (Peric et al., 2021). Its exact role is still being studied.

7. Treatment

Treatment should be planned at a specialist ocular oncology centre.

Surgery

The main treatment is a “no-touch” excision: the surgeon removes the tumour with a margin of healthy tissue without handling the tumour itself, to avoid spreading cells.

Step Purpose
Excision with margins Removes the tumour in one piece
Alcohol to the corneal surface Loosens and removes surface cells near the cornea
Freezing (cryotherapy) to the edges Destroys microscopic cells left at the margins
Covering the wound With a graft of conjunctiva or amniotic membrane

Additional local treatments

Treatment When it is used
Mitomycin C eye drops For residual PAM or to lower recurrence risk
Interferon eye drops An alternative topical treatment
Plaque brachytherapy Radiation placed on the eye for deeper or residual disease
External beam or proton radiotherapy For widespread or recurrent disease

Advanced local disease

If the melanoma has grown into the eye socket or is too widespread to remove, an operation called orbital exenteration, which removes the eye and surrounding tissues, may be needed. This is now less common thanks to earlier diagnosis and other treatments.

Treatment for spread

Situation Options
Lymph node spread Surgery to the neck or parotid nodes, sometimes radiotherapy
Distant spread Immunotherapy such as PD-1 and CTLA-4 inhibitors
BRAF mutation present BRAF and MEK inhibitor tablets
KIT mutation present KIT inhibitors in selected cases

Because conjunctival melanoma is genetically similar to skin melanoma, many of the newer skin melanoma drugs appear to work for it too (Grimes et al., 2020).

Side effects

Treatment Possible side effects
Surgery and cryotherapy Redness, discomfort, scarring, dry eye
Mitomycin C Stinging, redness, surface irritation
Radiotherapy Dry eye, cataract, eyelash loss
Exenteration Loss of the eye; an artificial eye or prosthesis is fitted
Immunotherapy Tiredness, rash, inflammation of organs

8. Outlook (prognosis)

Most people with conjunctival melanoma survive, but the tumour can recur locally and a minority develop spread.

In the 382-patient series, the risk of metastasis at 10 years was about a quarter for melanomas arising from PAM or a naevus, compared with nearly half for de novo tumours. Melanoma-related death at 10 years was about 9% for the first two groups and about 35% for de novo melanoma (Shields et al., 2011).

Factor Effect on outlook
De novo origin Higher risk
Non-bulbar location (fornix, eyelid, caruncle) Higher risk
Nodular, thick tumour Higher risk
Invasion of the orbit Higher risk
Ulceration Higher risk
Local recurrence Higher risk of later spread
Thin bulbar tumour fully removed Best outlook

9. Follow-up

Follow-up Purpose
Eye examination every 3-6 months at first Checks for recurrence and new PAM
Clinical photographs Compare changes over time
Lymph node checks By examination and sometimes ultrasound
Scans for higher-risk tumours Look for distant spread
Lifelong eye checks New lesions can appear many years later

10. Living with conjunctival melanoma

  • Look at your eyes in a mirror regularly, lifting the lids, and report new spots
  • Wear sunglasses that block ultraviolet light
  • Use lubricating drops for dry or gritty eyes after treatment
  • Attend every follow-up appointment
  • Ask about support if you need an artificial eye or have changes to your appearance
  • Seek help from eye cancer and melanoma charities

11. Frequently asked questions

Question Answer
Is it the same as eye melanoma inside the eye? No; uveal melanoma is a different disease
Will I lose my eye? Most people keep their eye; removal is needed only for advanced disease
Will I lose my vision? Usually not, unless the tumour or treatment affects the cornea
Is it inherited? Not usually
Can it come back? Yes, locally, which is why lifelong checks are needed
Can a freckle on my eye become cancer? Rarely; any change should be checked
Do skin melanoma drugs work? Often, because the gene changes are similar

12. Questions to ask your care team

  • Where did my melanoma start, and is it bulbar or non-bulbar?
  • How thick was it, and were the margins clear?
  • Do I need eye drops or radiotherapy after surgery?
  • Should I have a sentinel lymph node biopsy?
  • Does my tumour have a BRAF or other mutation?
  • How often will I need eye and node checks?

Resources

  1. Butt, K. et al. (2024) ‘Conjunctival melanoma: a clinical review and update’, Cancers, 16(18), 3121.
  2. Grimes, J.M. et al. (2020) ‘Conjunctival melanoma: current treatments and future options’, American Journal of Clinical Dermatology, 21(3), pp. 371-381.
  3. Peric, B. et al. (2021) ‘Sentinel node biopsy for conjunctival melanoma; single centre experience and review of current literature’, Cancer Control, 28, 10732748211042116.
  4. Shields, C.L. et al. (2011) ‘Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases’, Ophthalmology, 118(2), pp. 389-395.

Prepared by the editorial team, October 2026.